CALGARY, Dec. 22 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') announced today that Dr. Matt Coffey has been appointed Chief Operating Officer (COO). Dr. Coffey was formerly Chief Scientific Officer of Oncolytics.
"On behalf of the Board of Directors of Oncolytics, I am pleased to announce this appointment," said Dr. Brad Thompson, President, CEO and Chairman of the Board. "Dr. Coffey has played an integral role in the development of Oncolytics and its proprietary product, REOLYSIN®."
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN®, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com